Loading...
•
Jun 30, 2022
Zai Lab Q2 2022 Earnings Report
Announced second quarter 2022 financial results, highlighted by key pipeline milestones and continued revenue growth led by ZEJULA.
Key Takeaways
Zai Lab reported strong second-quarter results with continued revenue growth, particularly from ZEJULA. The company achieved key pipeline milestones, including the BLA acceptance of efgartigimod in China and positive topline results for the KarXT Phase 3 EMERGENT-2 trial. The company's cash position remains strong at $1.26 billion.
BLA acceptance of efgartigimod by China’s NMPA.
Positive topline results for the KarXT Phase 3 EMERGENT-2 trial.
Continued revenue growth led by ZEJULA.
Strong balance sheet with a cash position of $1.26 billion.
Zai Lab
Zai Lab
Zai Lab Revenue by Segment
Revenue by Segment
ZEJULA Revenue
CapyFin.comNUZYRA Revenue
CapyFin.com Forward Guidance
Zai Lab is on track to deliver its remaining 2022 corporate priorities, including an NDA submission to the NMPA for sulbactam-durlobactam, advancing ZL-1102 into full global development, and seeking NRDL inclusion for QINLOCK and NUZYRA.
Positive Outlook
- NDA submission to the NMPA for sulbactam-durlobactam.
- Advancing ZL-1102 (anti-IL-17A Humabody®) into full global development.
- Seeking NRDL inclusion for QINLOCK.
- Seeking NRDL inclusion for NUZYRA.
Revenue & Expenses
Visualization of income flow from segment revenue to net income